DRI Healthcare Trust (TSE:DHT.UN) Given Average Recommendation of “Buy” by Analysts

DRI Healthcare Trust (TSE:DHT.UN) has earned an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is C$21.83.

DHT.UN has been the topic of a number of research reports. National Bankshares raised their price target on DRI Healthcare Trust from C$22.00 to C$23.50 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Scotiabank lifted their target price on DRI Healthcare Trust from C$22.00 to C$24.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Raymond James upgraded DRI Healthcare Trust from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from C$22.00 to C$24.00 in a research report on Friday, March 1st. CIBC boosted their price target on DRI Healthcare Trust from C$19.00 to C$19.50 and gave the company an “outperform” rating in a report on Friday, March 1st. Finally, Stifel Nicolaus boosted their price objective on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock a “buy” rating in a research note on Friday, March 1st.

DRI Healthcare Trust Trading Up 38.6 %

Shares of DHT.UN opened at C$17.32 on Wednesday. DRI Healthcare Trust has a 52 week low of C$7.55 and a 52 week high of C$17.43. The stock has a 50 day moving average of C$15.61.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.